详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Laboratory Safety of Dupilumab,and Its Effect on Inflammatory Biomarkers,in Chinese Adults With Moderate-to-Severe Atopic Dermatitis:An Analysis of a Randomized,Double-Blind Phase Ⅲ Study

文献详情

资源类型：

收录情况： ◇ 统计源期刊 ◇ 卓越：梯队期刊 ◇ 中华系列

作者：

单位： [1]Department of Dermatology,Peking University People's Hospital,Beijing 100044,China [2]Hangzhou First People's Hospital,Hangzhou,Zhejiang 310006,China [3]The Second Xiangya Hospital of Central South University,Changsha,Hunan 410011,China [4]The First Hospital of China Medical University,Shenyang,Liaoning 110001,China [5]Wuxi Second People's Hospital,Wuxi,Jiangsu 214002,China [6]Hospital for Skin Diseases,Institute of Dermatology,Chinese Academy of Medical Sciences,Nanjing,Jiangsu 210042,China [7]Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China [8]Huashan Hospital,Fudan University Shanghai200040,China [9]Shanghai Skin Disease Hospital,Shanghai 200040,China [10]The Southwest Hospital of AMU,Chongqing 400038,China [11]Peking University First Hospital,Beijing 100034,China [12]Jinan Central Hospital,Jinan,Shandong 250013,China [13]Peking University Third Hospital,Beijing 100191,China [14]University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong 518040,China [15]Changhai Hospital of Shanghai,Shanghai 200433,China [16]Ningbo No.2 Hospital,Ningbo,Zhejiang 315099,China [17]The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi 710004,China [18]Tianjin Medical University General Hospital,Tianjin 300052,China [19]Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China [20]Research&Development,Sanofi,Bridgewater,NJ 08807,USA [21]Research&Development,Regeneron,Tarrytown,NY 10591,USA [22]Medical,Sanofi China,Shanghai200040,China

出处：

DOI：

ISSN：

关键词： atopic dermatitis dupilumab laboratory safety Chinese

语种：

第一作者：

第一作者单位： [1]Department of Dermatology,Peking University People's Hospital,Beijing 100044,China

通讯作者：

通讯机构： [1]Department of Dermatology,Peking University People's Hospital,Beijing 100044,China [*1]Department of Dermatology, Peking University People’s Hospital, Beijing 100044, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]LABORATORY SAFETY OF DUPILUMAB AND ITS EFFECT ON INFLAMMATORY BIOMARKERS IN ADULT CHINESE PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND PHASE III STUDY [2]Potential biomarkers of atopic dermatitis [3]The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis [4]EFFICACY AND SAFETY OF DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHINESE ADULTS: A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL [5]Changes of Thymus and Activation-Regulated Chemokine in Type 2 Inflammatory Disease Patients with Dupilumab Treatment [6]New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration [7]面部脂溢性皮炎及特应性皮炎调查及特点分析 [8]Prevalence and Clinical Features of Atopic Dermatitis in China [9]Clinical Application of the UK Working Party's Criteria for the Diagnosis of Atopic Dermatitis in the Chinese Population by Age Group [10]Prevalence and clinical features of adult atopic dermatitis in tertiary hospitals of China